sufentanil has been researched along with phenytoin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bonhomme, V; Brichant, JF; Hans, P; Ledoux, D | 1 |
1 review(s) available for sufentanil and phenytoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sufentanil and phenytoin
| Article | Year |
|---|---|
Effect of plasma anticonvulsant level on pipecuronium-induced neuromuscular blockade: preliminary results.
Topics: Adult; Anesthesia; Anticonvulsants; Carbamazepine; Drug Interactions; Electrocardiography; Humans; Nerve Block; Neuromuscular Blocking Agents; Phenytoin; Pipecuronium; Sufentanil | 1995 |
3 other study(ies) available for sufentanil and phenytoin
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |